Repaglinide

Results: 16



#Item
11Shiew-Mei Huang: Regulatory Issues - An FDA Perspective

Shiew-Mei Huang: Regulatory Issues - An FDA Perspective

Add to Reading List

Source URL: www.fda.gov

Language: English
12HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PrandiMet safely and effectively. See full prescribing information for PrandiMet. ·················

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PrandiMet safely and effectively. See full prescribing information for PrandiMet. ·················

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-04-26 16:06:05
13C:�a�Documents�741S18AP.doc

C:aDocuments741S18AP.doc

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 16:05:33
14HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PrandiMet safely and effectively. See full prescribing information for PrandiMet. PrandiMet® (repaglinide and metfo

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PrandiMet safely and effectively. See full prescribing information for PrandiMet. PrandiMet® (repaglinide and metfo

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-03-06 13:54:12
15PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only

PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-07-31 23:22:50
16

PDF Document

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:08:35